Trial Profile
An open-label, multi-center, three arm randomized study to investigate the safety and efficacy on progression-free survival of RO5072759 + chlorambucil (GClb) compared to rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Chlorambucil; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Results of meta-analysis of randomized controlled trials ((NCT01010061), ALLIANCE (NCT01886872), MABLE (NCT01056510), and SEQUOIA (NCT03336333)) assessing relative efficacy of zanubrutinib compared with standard frontline treatments for chronic lymphocytic leukemia, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.